From 2013.igem.org

Assay Validation

For a detailed, graphical explanation of the MaGellin work flow, please download the MaGellin Workflow Specifications Sheet, which includes all of the steps in the MaGellin workflow.

Standardized Bisulfite Sequencing Primers. Bisulfite sequencing is a good next step to further characterize functional site-specific methylases but it is inherently very difficult to design good primers. People will use advanced algorithms for primer design, and are still not guaranteed to be successful for some sequences. We went through 8 sets of primers, most of which did not show the proper bias to amplify only bisulfite converted DNA. Primer Set 2 was successful and is included with our MaGellin plasmid, much like VF and VR are included as standardized biobrick sequencing primers (Figure 3).

In Vitro. First, we tested MaGellin with a purified methyltransferase in vitro. The results made it clear that MaGellin can detect methylation, at both the “target” and “off-target” site (Figure 4). MaGellin is also sensitive to various degrees of methylation (Figure 5). These experiments helped us optimize the ideal amount of plasmid and restriction enzyme to use in any study moving forward.

In vivo. Then, we expressed M.SssI in vivo and compared it with purified M.SssI used on the plasmid in vitro. In both cases, we saw similar full methylation of the plasmid, confirming that MaGellin can express methylases and report their activity in vivo (Figure 6).

Summary

We have created MaGellin, a new technology that facilitates screening novel DNA binding domain – methyltransferase fusion proteins
1. Our assay is less expensive and faster than existing methods
2. We have eliminated noise associated with previous studies
3. We have a system with clear input/output
4. Our assay lends itself to high throughput screening of many different proteins
5. We are releasing it alongside an open source data analysis software package which streamlines the entire screening process

</br> </br> For a detailed, graphical explanation of the MaGellin work flow, please download the <a href="https://static.igem.org/mediawiki/2013/e/e5/Spec_Sheet.pdf">MaGellin Workflow Specifications Sheet</a>, which includes all of the steps in the MaGellin workflow. </br> </br> </br> Our Team’s Solution. In order to address the challenges associated with developing new site-specific methylase proteins, our team proposed several different strategies. First, we proposed a migration away from mammalian systems and into E. coli. E. coli does not have a native cytosine methyltransferase, and therefore offers a noise-free environment for methylation studies. Any methylation of CpG sites in E Coli would be a product of a candidate engineered protein rather than the native organism. Second, we envisioned a modular one-plasmid system that can be employed for quickly and cheaply screening the activity and specificity of any DNA binding domain – methyltransferase fusion protein. This plasmid-based methylation assay is called MaGellin. </br> </br> </br>

<figure><img border="0" src="" alt="MaGellin" width="700" height="395"><figcaption>The MaGellin plasmid includes all the features needed to clone, express, and assay site-specific methylases.</figcaption></figure>

</br> </br> </br> Plasmid Features. To accommodate the MaGellin assay, our team designed a plasmid with several key features:

1. CpG Methyltransferase (M.SssI) with a generic linker sequence in the cloning site. For a working fusion protein and assay, only a DNA binding domain must be cloned into the plasmid. This inherently standardizes MaGellin and lessens the time a user of the assay must spend cloning.
2. Multiple cloning site downstream of T7 promoter for orthogonal expression of fusion protein in T7 Express competent E. coli.
3. Cloning site for a smaller DNA sequence, specific to the fusion protein being screened – named the “target site”, where the protein will bind. This can be the binding site for a CRISPR-Cas, TALE, Zinc Finger, or transcription factor
4. AvaI restriction site 4 bases downstream of the target site – the AvaI restriction enzyme is blocked by methylated CpG sites, thus screening for site specific methylation becomes equivalent to screening for AvaI digestion
5. AvaI restriction site sufficiently further downstream of the target site – named the off-target site. This site screens for non-specific DNA methylation as it is spatially removed from where the fusion protein binds to the plasmid.
6. XbaI site for linearization of the plasmid. Linearizing the plasmid simplifies analysis of the AvaI digestion by gel electrophoresis.
7. Validated bisulfite conversion primer binding sites, so users do not need to go through the time-consuming primer design process if they choose to fortify MaGellin’s results with bisulfite sequencing results
8. sgRNA cloning site for users who want to target a CRISPR-Cas binding domain. The sgRNA is constitutively expressed and can be swapped by restriction digest.
9. Validated bisulfite conversion primers for users who choose to advance to bisulfite sequencing, for even higher resolution in detecting methylation, after proving their enzyme’s efficacy with our MaGellin assay.
10. Kanamycin resistance as a selection marker

</br> </br> </br> Noiseless Chassis. After cloning this plasmid, we faced the challenge of choosing the correct cell line for the assay. We chose to transform into T7 Express cells for several reasons:

1. T7 RNA Polymerase in the lac operon allows us to turn on expression of fusion protein after induction with IPTG
2. In the T7 Express cell line, genes for several restriction enzymes known to target methylated DNA are knocked out (McrA-, McrBC-, EcoBr-m-, Mrr-). This ensures that our assay plasmid is not cleaved in vivo. Results are difficult, if not impossible, to interpret in the commonly used BL21 cell line.

</br> </br> </br> MaGellin Workflow. The workflow for screening new fusion proteins with the one plasmid MaGellin bacterial system is as follows:

Assemble the MaGellin backbone together with a DNA-binding protein and target sequence of your choosing.

Upload and analyze the gel photo using the MaGellin Software Package. </li>

1. Look for 3 distinct band patterns that correspond to specific and interpretable methylation outcomes.
1. The presence of large one band corresponds to non-site-specific DNA methylation (AvaI was blocked at both the target and off target sites, and thus only XbaI cut the plasmid)
2. The presence of two bands corresponds to site-specific DNA methylation (AvaI was only blocked at the target site, thus AvaI cut in the off target site and XbaI cut the plasmid)
3. The presence of three bands corresponds to no DNA methylation – or an inactive fusion protein (AvaI was not blocked at either the target or off target sites and XbaI cut the plasmid)

</br> </br>

<figure><img border="0" src="" alt="Workflow" width="600" height="1000"><figcaption></figcaption></figure>

</br> </br> Standardized Bisulfite Sequencing Primers. Bisulfite sequencing is a good next step to further characterize functional site-specific methylases but it is inherently very difficult to design good primers. People will use advanced algorithms for primer design, and are still not guaranteed to be successful for some sequences. We went through 8 sets of primers, most of which did not show the proper bias to amplify only bisulfite converted DNA. Primer Set 2 was successful and is included with our MaGellin plasmid, much like VF and VR are included as standardized biobrick sequencing primers (Figure 3). </br> </br> </br>

<figure><img border="0" src="" alt="InVitro" width="600" height="395"><figcaption>Figure 4: Plasmid DNA treated in vitro with purified M.SssI. The first three lanes were not treated and show zero methylation detection by our assay. The last three lanes were methylated and show 100% methylation. This figure validates that MaGellin is capable of clear input/output.</figcaption></figure>

</br> </br> </br> In Vitro. First, we tested MaGellin with a purified methyltransferase in vitro. The results made it clear that MaGellin can detect methylation, at both the “target” and “off-target” site (Figure 4). MaGellin is also sensitive to various degrees of methylation (Figure 5). These experiments helped us optimize the ideal amount of plasmid and restriction enzyme to use in any study moving forward. </br> </br> </br>

<figure><img border="0" src="" alt="Timecourse" width="600" height="395"><figcaption>Figure 5: Plasmid DNA treated in vitro with purified M.SssI. Each lane was treated for a different amount of time, this figure shows MaGellin's sensitivity.</figcaption></figure>

</br> </br> </br> In vivo. Then, we expressed M.SssI in vivo and compared it with purified M.SssI used on the plasmid in vitro. In both cases, we saw similar full methylation of the plasmid, confirming that MaGellin can express methylases and report their activity in vivo (Figure 6). </br> </br> </br>

<figure><img border="0" src="" alt="InVivo" width="600" height="395"><figcaption>Figure 6: M.SssI expressed in vivo compared with in vitro methylation.</figcaption></figure>

</br> </br> </br> Summary

We have created MaGellin, a new technology that facilitates screening novel DNA binding domain – methyltransferase fusion proteins
1. Our assay is less expensive and faster than existing methods
2. We have eliminated noise associated with previous studies
3. We have a system with clear input/output
4. Our assay lends itself to high throughput screening of many different proteins
5. We are releasing it alongside an open source data analysis software package which streamlines the entire screening process

       </div>
   </div>

</body> <script> </script> </html>

Retrieved from "http://2013.igem.org/Team:Penn/AssayValidation"